LAUSR

ABSTRACT Sodium‐glucose cotransporter 1 (SGLT1) is the primary transporter for glucose absorption from digested nutrients in the gastrointestinal tract. Intestinal SGLT1 inhibition reduces post‐prandial hyperglycemia and enhances the increase of plasma glucagon‐like peptide‐1 (GLP‐1) levels. SGL5213 is a novel and potent intestinal SGLT1 inhibitor. This study characterizes the pharmacological profiles of SGL5213 in rodents. Orally administered SGL5213 was hardly absorbed and its distribution was restricted to the gastrointestinal lumen. SGL5213 significantly improved post‐prandial hyperglycemia in streptozotocin (STZ)‐induced diabetic rats at doses of 1 mg/kg or more. After the oral administration of starch, SGL5213 increased the amount of residual glucose in the small intestine at 1–3 h and in the cecum and colon at 3–9 h by inhibiting glucose absorption and allowing the unabsorbed glucose to be delivered into the lower‐gastrointestinal tract. In the vehicle group, the plasma total GLP‐1 (tGLP‐1) and tGLP‐2 levels increased at 15 min and the plasma total glucose‐dependent insulinotropic polypeptide (tGIP) level increased at 1 h after meal loading. SGL5213 at doses of 0.1 mg/kg or more enabled the plasma levels of tGLP‐1 and tGLP‐2 to be retained for a period of 1–6 h, compared with the vehicle group. In contrast, SGL5213 at doses of 0.3 mg/kg or more suppressed the plasma tGIP elevation after meal loading. This study demonstrated for the first time that an intestinal SGLT1 inhibitor enhanced post‐prandial plasma GLP‐2 secretion. These results suggest that SGL5213 might exhibit a useful pharmacological efficacy through the physiological actions of GLP‐1 and GLP‐2.